Molecular Templates, Inc.
MTEM Real Time Price USDRecent trades of MTEM by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by MTEM's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: De-immunized shiga toxin a subunit effector polypeptides for applications in mammals Aug. 20, 2024
-
Patent Title: Mhc class i epitope delivering polypeptides Jul. 16, 2024
-
Patent Title: Pd-l1-binding molecules comprising shiga toxin a subunit scaffolds Mar. 05, 2024
-
Patent Title: Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation Jan. 02, 2024
-
Patent Title: Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes Aug. 09, 2022
-
Patent Title: Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation Jul. 19, 2022
-
Patent Title: De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same Jun. 21, 2022
-
Patent Title: Mhc class i epitope delivering polypeptides Apr. 26, 2022
-
Patent Title: Multivalent cd20-binding molecule comprising shiga toxin a subunit effector polypeptides and enriched compositions thereof Feb. 15, 2022
-
Patent Title: Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds Jan. 18, 2022
-
Patent Title: Cd20-binding proteins comprising shiga toxin a subunit effector regions for inducing cellular internalization and methods using same Oct. 12, 2021
-
Patent Title: Pd-l1 -binding molecules comprising shiga toxin a subunit scaffolds Oct. 05, 2021
-
Patent Title: Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof Aug. 31, 2021
-
Patent Title: Cell-targeting molecules comprising protease-cleavage resistant, shiga toxin a subunit effector polypeptides and carboxy-terminal moieties Oct. 27, 2020
-
Patent Title: Predictive biomarker for hypoxia-activated prodrug therapy Sep. 01, 2020
-
Patent Title: Aziridine containing dna alkylating agents Jun. 02, 2020
-
Patent Title: Th-302 solid forms and methods related thereto May. 19, 2020
-
Patent Title: Cd20-binding immunotoxins for inducing cellular internalization and methods using same Oct. 22, 2019
-
Patent Title: Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity Sep. 24, 2019
-
Patent Title: Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof Aug. 27, 2019
-
Patent Title: Th-302 solid forms and methods related thereto Nov. 20, 2018
-
Patent Title: Predictive biomarker for hypoxia-activated prodrug therapy Sep. 11, 2018
-
Patent Title: Cytotoxic heteromeric protein combinatorial libraries May. 11, 2010
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of MTEM in WallStreetBets Daily Discussion
Recent insights relating to MTEM
Recent picks made for MTEM stock on CNBC
ETFs with the largest estimated holdings in MTEM
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view MTEM Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.